Company News »

NeuroMetrix CEO to Present at 29th Annual Meeting of Japan Society of Diabetic Complications

Business Wire
Share on StockTwits
Published on

NeuroMetrix, Inc. (Nasdaq: NURO), today announced that Shai N. Gozani M.D., Ph.D., NeuroMetrix President and Chief Executive Officer, will participate in the 29th Annual Meeting of The Japan Society of Diabetic Complications to be held in Tokyo on October 3 and 4, 2014. The Japan Society of Diabetic Complications is a part of The Japan Diabetes Society which was established in 1958 to promote diabetes-related academic research and treatment programs. The organization has over 16,000 members and works in collaboration with other international organizations including the International Diabetes Federation (IDF), the American Diabetes Association (ADA), and the European Association for the Study of Diabetes (EASD). The Annual Meeting of the Japan Society of Diabetic Complications is one of the major events of the Japan Diabetes Society.

Dr. Gozani will attend the Diabetic Complications Meeting where he will present a research study entitled “Association of Median and Sural Nerve Conduction in Patients with Diabetes”. This study is important because it links clinical work for the aldose reductase inhibitor, Epalrestat, a marketed pharmaceutical in Japan for patients with diabetic neuropathy with the diagnostic capability of the NeuroMetrix NC-stat DPNCheck(R) device for detection of peripheral neuropathies including diabetic peripheral neuropathy (DPN). Dr Gozani will also participate in a round-table discussion with several key opinion leaders in Japan who focus on clinical research and treatment of patients with diabetes.

About NeuroMetrix

NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The Company has a major focus on diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The Company markets the SENSUS(R) device for treating chronic pain, focusing on physicians managing patients with neuropathic pain such as painful diabetic neuropathy. The Company also markets DPNCheck(R), which is a rapid, accurate, and quantitative point-of-care test for peripheral neuropathies such as diabetic neuropathy. This product is used to detect neuropathies at an early stage and to guide treatment. For more information, please visit or

Share on StockTwits